Cargando…
Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditio...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192119/ https://www.ncbi.nlm.nih.gov/pubmed/32360580 http://dx.doi.org/10.1016/j.phrs.2020.104850 |
_version_ | 1783527965604184064 |
---|---|
author | Ma, Qinhai Pan, Weiqi Li, Runfeng Liu, Bin Li, Chufang Xie, Yuqi Wang, Zhoulang Zhao, Jin Jiang, Haiming Huang, Jicheng Shi, Yongxia Dai, Jun Zheng, Kui Li, Xiaobo Yang, Zifeng |
author_facet | Ma, Qinhai Pan, Weiqi Li, Runfeng Liu, Bin Li, Chufang Xie, Yuqi Wang, Zhoulang Zhao, Jin Jiang, Haiming Huang, Jicheng Shi, Yongxia Dai, Jun Zheng, Kui Li, Xiaobo Yang, Zifeng |
author_sort | Ma, Qinhai |
collection | PubMed |
description | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacological properties, such as anti-inflammatory, antiviral and immunomodulatory activities. However, little is known about the antiviral effect of LS against SARS-CoV-2. Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host’s immune response. The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque reduction assay. The number of virions of SARS-CoV-2 was observed under transmission electron microscope after treatment with LS. Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the number of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Moreover, the expression of the key proteins in the NF-κB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-κB p65, p-IκBα and p-p38 MAPK, while increasing the expression of IκBα. These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-κB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease. |
format | Online Article Text |
id | pubmed-7192119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71921192020-04-30 Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway Ma, Qinhai Pan, Weiqi Li, Runfeng Liu, Bin Li, Chufang Xie, Yuqi Wang, Zhoulang Zhao, Jin Jiang, Haiming Huang, Jicheng Shi, Yongxia Dai, Jun Zheng, Kui Li, Xiaobo Yang, Zifeng Pharmacol Res Article Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacological properties, such as anti-inflammatory, antiviral and immunomodulatory activities. However, little is known about the antiviral effect of LS against SARS-CoV-2. Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host’s immune response. The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque reduction assay. The number of virions of SARS-CoV-2 was observed under transmission electron microscope after treatment with LS. Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the number of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Moreover, the expression of the key proteins in the NF-κB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-κB p65, p-IκBα and p-p38 MAPK, while increasing the expression of IκBα. These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-κB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease. Elsevier Ltd. 2020-08 2020-04-30 /pmc/articles/PMC7192119/ /pubmed/32360580 http://dx.doi.org/10.1016/j.phrs.2020.104850 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Ma, Qinhai Pan, Weiqi Li, Runfeng Liu, Bin Li, Chufang Xie, Yuqi Wang, Zhoulang Zhao, Jin Jiang, Haiming Huang, Jicheng Shi, Yongxia Dai, Jun Zheng, Kui Li, Xiaobo Yang, Zifeng Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway |
title | Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway |
title_full | Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway |
title_fullStr | Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway |
title_full_unstemmed | Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway |
title_short | Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway |
title_sort | liu shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus sars-cov-2 via suppression of nf-κb signaling pathway |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192119/ https://www.ncbi.nlm.nih.gov/pubmed/32360580 http://dx.doi.org/10.1016/j.phrs.2020.104850 |
work_keys_str_mv | AT maqinhai liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT panweiqi liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT lirunfeng liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT liubin liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT lichufang liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT xieyuqi liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT wangzhoulang liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT zhaojin liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT jianghaiming liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT huangjicheng liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT shiyongxia liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT daijun liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT zhengkui liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT lixiaobo liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway AT yangzifeng liushencapsuleshowsantiviralandantiinflammatoryabilitiesagainstnovelcoronavirussarscov2viasuppressionofnfkbsignalingpathway |